DK2222669T3 - Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip) - Google Patents

Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip)

Info

Publication number
DK2222669T3
DK2222669T3 DK08864021.4T DK08864021T DK2222669T3 DK 2222669 T3 DK2222669 T3 DK 2222669T3 DK 08864021 T DK08864021 T DK 08864021T DK 2222669 T3 DK2222669 T3 DK 2222669T3
Authority
DK
Denmark
Prior art keywords
oxadiazold
sphingosin
sip
phosphate
derivatives
Prior art date
Application number
DK08864021.4T
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
Christopher Norbert Johnson
John Skidmore
Ian David Wall
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0725120A external-priority patent/GB0725120D0/en
Priority claimed from GB0821918A external-priority patent/GB0821918D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK2222669T3 publication Critical patent/DK2222669T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK08864021.4T 2007-12-21 2008-12-19 Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip) DK2222669T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0725120A GB0725120D0 (en) 2007-12-21 2007-12-21 Compounds
GB0821918A GB0821918D0 (en) 2008-12-01 2008-12-01 Compounds
PCT/EP2008/067965 WO2009080725A1 (en) 2007-12-21 2008-12-19 Oxadiazole derivatives active on sphingosine-1-phosphate (sip)

Publications (1)

Publication Number Publication Date
DK2222669T3 true DK2222669T3 (da) 2013-10-28

Family

ID=40342566

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08864021.4T DK2222669T3 (da) 2007-12-21 2008-12-19 Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip)

Country Status (29)

Country Link
US (2) US8222245B2 (da)
EP (1) EP2222669B1 (da)
JP (1) JP2011506569A (da)
KR (1) KR20100108566A (da)
CN (1) CN101945863B (da)
AR (1) AR069916A1 (da)
AU (1) AU2008339988B2 (da)
BR (1) BRPI0820131A2 (da)
CA (1) CA2710130A1 (da)
CO (1) CO6290646A2 (da)
CR (1) CR11579A (da)
DK (1) DK2222669T3 (da)
DO (1) DOP2010000194A (da)
EA (1) EA017691B1 (da)
ES (1) ES2434730T3 (da)
HK (1) HK1142062A1 (da)
HR (1) HRP20130957T1 (da)
IL (1) IL206235A0 (da)
MA (1) MA31924B1 (da)
NZ (1) NZ585996A (da)
PE (1) PE20091339A1 (da)
PL (1) PL2222669T3 (da)
PT (1) PT2222669E (da)
RS (1) RS53038B (da)
SI (1) SI2222669T1 (da)
TW (1) TWI415847B (da)
UY (1) UY31570A1 (da)
WO (1) WO2009080725A1 (da)
ZA (1) ZA201003963B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
PL2361250T3 (pl) 2008-12-22 2014-01-31 Merck Patent Gmbh Nowe polimorficzne formy diwodorofosforanu 6-(1-metylo-1H-pirazolo-4-ylo)-2-{3-[5-(2-morfolino-4-ylo-etoksy)-pirymidyno-2-ylo]-benzylo}2H-pirydazyno-3-onowego oraz sposoby ich otrzymywania
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011028927A1 (en) * 2009-09-04 2011-03-10 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ, インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1,3,4-噁二唑化合物的合成方法和其药物用途
NO3175985T3 (da) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) * 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
WO2016087370A1 (en) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
JP2024506387A (ja) * 2021-02-10 2024-02-13 アイカーン スクール オブ メディスン アット マウント サイナイ 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ[2,3‐b]ピリジン系HIPK2阻害剤
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP1335915B1 (en) 2000-11-14 2008-01-02 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
WO2004113330A1 (en) 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0414795D0 (en) 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
CA2591399C (en) 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
KR101382733B1 (ko) * 2005-03-23 2014-04-14 액테리온 파마슈티칼 리미티드 면역조절물질로서의 수첨 벤조(c) 티오펜 유도체
WO2006100633A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
NZ563522A (en) * 2005-04-22 2010-01-29 Daiichi Sankyo Co Ltd Heterocyclic compound with immunosuppressive activity
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
AR058221A1 (es) 2005-11-24 2008-01-23 Glaxo Group Ltd Benzazepinas inhibidoras del factor xa, composicion farmaceutica que la comprende y su uso para fabricar un medicamento
BRPI0709866B8 (pt) * 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CN101945863B (zh) 2013-07-03
TWI415847B (zh) 2013-11-21
SI2222669T1 (sl) 2013-10-30
CN101945863A (zh) 2011-01-12
EP2222669A1 (en) 2010-09-01
IL206235A0 (en) 2010-12-30
NZ585996A (en) 2012-06-29
EP2222669B1 (en) 2013-08-21
ES2434730T3 (es) 2013-12-17
US8222245B2 (en) 2012-07-17
AU2008339988A1 (en) 2009-07-02
CR11579A (es) 2010-09-03
PL2222669T3 (pl) 2014-01-31
MA31924B1 (fr) 2010-12-01
EA201070782A1 (ru) 2010-12-30
HRP20130957T1 (hr) 2013-11-08
WO2009080725A1 (en) 2009-07-02
EA017691B1 (ru) 2013-02-28
RS53038B (en) 2014-04-30
TW200940531A (en) 2009-10-01
ZA201003963B (en) 2011-11-30
BRPI0820131A2 (pt) 2015-05-12
JP2011506569A (ja) 2011-03-03
CO6290646A2 (es) 2011-06-20
PE20091339A1 (es) 2009-09-26
US20100273771A1 (en) 2010-10-28
CA2710130A1 (en) 2009-07-02
KR20100108566A (ko) 2010-10-07
HK1142062A1 (en) 2010-11-26
DOP2010000194A (es) 2010-08-15
US20100174065A1 (en) 2010-07-08
PT2222669E (pt) 2013-10-28
AR069916A1 (es) 2010-03-03
AU2008339988B2 (en) 2013-09-26
UY31570A1 (es) 2009-05-29

Similar Documents

Publication Publication Date Title
DK2222669T3 (da) Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip)
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
ATE483711T1 (de) Spiroindolinonderivate
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0813836A2 (pt) Derivados pirazólicos
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
DK2134708T3 (da) 3-Cyano-4-(4-tetrahydropyranphenyl)-pyridin-2-on-derivater
ATE518837T1 (de) Indazolamidderivate
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
DK2152370T3 (da) Aryletherpyridazinonderivater
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
ATE519760T1 (de) Isoxazolimidazolderivate
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
DK2225233T3 (da) Oxadiazolderivat med virkning på sphingosin-1-phosphat (s1p)
ATE467626T1 (de) Indol-2-yl-piperazin-1-yl-methanon-derivate